CAMBRIDGE, Mass.--(BUSINESS WIRE)--Selventa™, which evolved from Genstruct®, Inc. today announced that representatives from the company will present strategies to optimizing project portfolio through early patient stratification and applying structured scientific language to analyze complex molecular data at industry conferences during the month of February. Selventa’s President and CEO, David de Graaf, Ph.D, and VP of Innovation and Knowledge, Dexter Pratt, respectively, will take part in the presentations.
